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Abstract: Patients with advanced COPD and acute or chronic respiratory failure are at high 
risk for death. Beyond pharmacological treatment, supplemental oxygen and mechanical ventila-
tion are major treatment options. This review describes the physiological concepts underlying 
respiratory failure and its therapy, as well as important treatment outcomes. The rationale for 
the controlled supply of oxygen in acute hypoxic respiratory failure is undisputed. There is also 
a clear survival beneﬁ  t from long-term oxygen therapy in patients with chronic hypoxia, while 
in mild, nocturnal, or exercise-induced hypoxemia such long-term beneﬁ  ts appear questionable. 
Furthermore, much evidence supports the use of non-invasive positive pressure ventilation in 
acute hypercapnic respiratory failure. It application reduces intubation and mortality rates, and the 
duration of intensive care unit or hospital stays, particularly in the presence of mild to moderate 
respiratory acidosis. COPD with chronic hypercapnic respiratory failure became a major indica-
tion for domiciliary mechanical ventilation, based on pathophysiological reasoning and on data 
regarding symptoms and quality of life. Still, however, its relevance for long-term survival has 
to be substantiated in prospective controlled studies. Such studies might preferentially recruit 
patients with repeated hypercapnic decompensation or a high risk for death, while ensuring 
effective ventilation and the patients’ adherence to therapy.
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Introduction
Chronic obstructive pulmonary disease (COPD) constitutes a major global health 
burden based on its high prevalence, exorbitant health-care costs, and signiﬁ  cant mortality 
(Halbert et al 2006; Jemal et al 2005; Mannino et al 2007). Recent meta-analyses and 
large multi-national epidemiological surveys, that covered many regions world-wide 
and used established spirometric deﬁ  nitions, suggested that the prevalence of COPD 
has even been underestimated (Buist et al 2007; Menezes et al 2005).
Despite the lower numbers of severe (Global Initiative for Chronic Obstructive Lung 
Disease (GOLD) III) and very severe COPD (GOLD IV) compared to milder forms, the 
advanced stages of the disease are requiring the by far largest proportion of health-care 
resources (Chapman et al 2006) due to excessive hospitalization, exacerbation and 
mortality rates (Ambrosino et al 2007a). Prognosis signiﬁ  cantly worsens in case of 
additional respiratory failure occurring either chronically or temporarily during an 
acute exacerbation. Survival is particularly reduced when ventilatory support becomes 
necessary (Ai-Ping et al 2005; Chu et al 2004). These patients merit special consider-
ation not only because of poor outcome and survival rates but also in view of several 
therapeutical options.
If applied in deﬁ  ned circumstances, these options can prolong life and/or improve 
functional capacity, symptoms, and health-related quality of life (Rabe et al 2007). It 
has to be taken in account, however, that these therapies by themselves can involve 
considerable health-care costs. Thus, they should be used in the most efﬁ  cient, 
evidence-based manner. Based on these considerations the present review focuses on 
clinically and pathophysiologically important aspects of the two major modalities for International Journal of COPD 2008:3(4) 606
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the treatment of acute or chronic respiratory failure in 
COPD: mechanical ventilation and oxygen therapy.
Deﬁ  nitions and pathophysiology
of respiratory failure
Commonly respiratory failure results from disturbances of 
gas exchange due to impairments in either oxygenation, or 
elimination of carbon dioxide, or both (Roussos et al 2003). 
For clinical routine purposes, respiratory failure is usually 
deﬁ  ned by an arterial oxygen tension (PaO2) of less than 
60 mmHg ( 8.0 kpa) and/or an arterial carbon dioxide 
tension (PaCO2) greater than 45 mmHg ( 6.0 kpa).
From a pathophysiological point of view the respiratory 
system comprises two major compartments: the lung as a 
gas exchange device and the ventilatory pump powering 
this device. Functional failure of the lung itself (type I 
respiratory failure) primarily results in arterial hypoxemia, 
associated with normal or even reduced levels of PaCO2 as 
a consequence of compensatory augmented ventilation. In 
contrast, ventilatory pump failure (type II (hypercapnic) 
respiratory failure) is caused by mechanical disadvantage 
(such as lung hyperinﬂ  ation in COPD), central nervous 
system abnormalities, or respiratory muscle dysfunction and 
leads to an elevation of PaCO2 levels, often in company with 
hypoxemia due to alveolar hypoventilation.
In COPD, as in other conditions of respiratory ill-
ness, respiratory failure can occur as acute, chronic, or 
acute-on-chronic failure. In addition to ventilation/perfusion 
inhomogeneities, lung hyperinﬂ  ation is a major factor in the 
pathogenesis of hypercapnic respiratory failure, being associ-
ated with a ﬂ  at diaphragm and thereby diminishing muscle 
efﬁ  ciency and increasing energy consumption (Calverley 
2003). In the chronic setting, patients with COPD often show 
a rapid shallow breathing. This presumably represents a key 
protective mechanism to prevent respiratory muscle fatigue, 
however at the price of an insufﬁ  cient alveolar ventilation 
(Roussos et al 2003). In severe COPD with markedly limited 
functional reserves, acute-on-chronic respiratory failure may 
aggravate the pre-existing chronic respiratory failure. This 
can happen when an acute deterioration of whatsoever origin, 
most often increased airway obstruction during acute exac-
erbation, poses an additional load on the respiratory system. 
The pre-existing mechanical disadvantage is further boosted 
by incomplete emptying of the lungs, leading to air trapping. 
This promotes a signiﬁ  cant intrinsic positive end-expiratory 
airway pressure (PEEPi) which further aggravates respira-
tory muscle dysfunction and enhances ventilation-perfusion 
mismatch (Smith et al 1988).
Principles of the treatment 
of respiratory failure
Naturally, the prophylactic strategies against respiratory 
failure in COPD comprise the avoidance or reduction of 
disease progression and the prevention or amelioration 
of exacerbations by vaccination (Alfageme et al 2006; 
Wongsurakiat et al 2004), anti-inﬂ  ammatory therapy (Burge 
et al 2000), long-acting bronchodilators (Mahler et al 1999; 
Niewoehner et al 2005), or their combination (Calverley et al 
2007). In the presence of an exacerbation the treatment of 
airway obstruction with bronchodilators (Bach et al 2001), 
and the administration of systemic steroids (Niewoehner et al 
1999) and antibiotics are basic in the management of acute 
respiratory failure. The practical aspects and therapeutic efﬁ  -
cacies of these interventions for treating acute exacerbations 
have recently been reviewed in detail (MacIntyre et al 2008) 
and are summarized in the current COPD-update provided 
by GOLD (Rabe et al 2007).
Once respiratory failure is imminent, or aggravated because 
it has been present before, the maintenance or improvement 
of gas exchange by additional non-pharmacological options 
is strongly recommended, among them most importantly 
oxygen supply. This basically aims at raising the fraction of 
inspired and taken-up oxygen to counteract acute or chronic 
hypoxia and to prevent or reduce tissue hypoxia. Signiﬁ  cant 
beneﬁ  ts for the patients are symptom relief and improved 
long-term survival. As a second major option, ventilatory 
support must be taken into consideration to raise alveolar 
ventilation and/or reduce mechanical load. This can be 
achieved either invasively or non-invasively in the inten-
sive/intermediate care unit (ICU), emergency department, 
or – for long-term use – at home.
Treatment of acute respiratory 
failure
Impact of non-invasive ventilation 
in acute respiratory failure
The onset of acute respiratory failure (ARF) in COPD 
generally marks a serious change in clinical state and is a fre-
quent cause of admissions to emergency and/or intensive care 
units (ICU). Even more, ARF is also associated with excess 
mortality both during the hospital stay and in the months 
following discharge from the hospital (Connors Jr et al 
1996; Seneff et al 1995). The long-term prognosis of 
patients with COPD and ARF particularly worsens if their 
clinical state calls for a ventilatory support, irrespective of 
whether this is applied invasively (Connors et al 1996) or International Journal of COPD 2008:3(4) 607
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non-invasively (Chu et al 2004). Despite these commonalities, 
the introduction of non-invasive ventilation must be consid-
ered as one of the major advances in respiratory medicine, 
with signiﬁ  cant consequences in terms of improved short- and 
long-term outcome (Plant et al 2003).
Acute hypercapnic respiratory failure following 
acute exacerbation
Among the non-invasive ventilation techniques, non-invasive 
positive pressure ventilation (NPPV) via nasal or facial mask 
or a helmet (Antonelli et al 2004) is meanwhile the therapy 
of choice for the treatment of acute hypercapnic respiratory 
failure in acute exacerbations of COPD. However, also 
negative pressure ventilation (via an iron lung) seems to be 
effective in avoiding endotracheal intubation and reducing 
the risk of death (Corrado et al 2002). Even more, also con-
tinuous positive airway pressure (CPAP) support – though 
not being a ventilation in the proper sense of the word – has 
been proven as useful during ARF in patients with COPD 
(Dial et al 2006).
Randomized clinical trials as summarized in meta-
analyses (Lightowler et al 2003; Peter et al 2002) and com-
prehensive reviews (Keenan et al 2003; Ram et al 2004) have 
clearly demonstrated that the supplementation of standard 
medical care by NPPV results in a lower mortality and risk for 
intubation. This is accompanied by a reduction in the number 
of hospital or ICU days compared to standard medical care 
only, which in particular might include intubation. The results 
make sense in view of the fact that non-invasive ventilation 
offers signiﬁ  cant advantages over invasive approaches, 
circumventing a number of serious complications that 
can occur after tracheal tube insertion or tracheostomy. 
Complications include the possibility of ventilator-induced 
lung injury and the elevated risk for respiratory infections, 
both of which are known to be associated with invasive 
mechanical ventilation (Ambrosino et al 2008).
Predictors of success/failure with non-invasive 
ventilation in acute respiratory failure
Despite the reported effectiveness of NPPV in patients with 
COPD and ARF, it should be noted that the beneﬁ  t from 
NPPV critically depends on the degree of hypercapnia and 
respiratory acidosis. Arterial pH seems to constitute the best 
marker reﬂ  ecting both the severity of ARF and the effect of 
NPPV in the acute setting (Plant et al 2003). In mild exacer-
bations of COPD (pH   7.35), NPPV seems to be of limited 
value and not being well tolerated by the patients, as indi-
cated by a randomized controlled trial (Keenan et al 2005). 
In accordance with these ﬁ  ndings, in patients with very severe 
ARF (pH   7.25) the rate of NPPV failure was inversely 
related to the severity of respiratory acidosis (Ambrosino 
et al 2008). This indicates that severe acidosis resulting 
from acute exacerbation is a relevant predictor for treatment 
failure of NPPV (Plant et al 2001), in addition to being a 
prognostic factor for mortality per se (Jeffrey et al 1992; 
Plant et al 2000).
In this regard, the ﬁ  ndings of recent clinical trials might 
seem surprising at the ﬁ  rst view (Diaz et al 2005a; Scala 
et al 2007). These studies suggested that a reduced level of 
consciousness in acute hypercapnic respiratory failure must 
not necessarily be taken as a contraindication for NPPV, as 
had been proposed previously (Mehta et al 2001). It should 
be clear, however, that not only experience with the tech-
nique and the type of patient involved is required, but also 
a close supervision and permanent stand-by in order to 
initiate immediate endotracheal intubation if NPPV is not 
effective within short time (Scala et al 2007). Irrespective of 
these possibilities, the most favorable results of NPPV in ARF 
due to acute exacerbation have been obtained when NPPV 
was employed in an early stage and in patients with moderate 
hypercapnic respiratory failure (pH 7.25–7.35) (Table 1).
In addition to the severity of failure as reﬂ  ected by pH, 
the presence of signiﬁ  cant comorbidities raises the prob-
ability of NPPV failure (Nava et al 2004). A large study of 
patients with COPD, in which a chart for NPPV failure was 
prospectively evaluated, revealed that in addition to low pH 
values low scores of the Glasgow Coma scale, high respira-
tory rates and high APACHE-II scores were related to NPPV 
failure (Confalonieri et al 2005). Another key indicator of 
failure seems to be the lack of improvement in clinical and 
gas exchange measures within the ﬁ  rst hour after initiation 
of NPPV (Garpestad et al 2007). There are further predic-
tors for NPPV failure that have been revealed during the 
last years and might be helpful for the decision on initiation 
and continuation of NPPV in patients with COPD and ARF 
(Table 1). Moreover, a number of contraindications such 
as persistent unconsciousness, hemodynamic instability, 
gastrointestinal or orofacial bleeding, a high risk for aspira-
tion, or the inability to protect the airways have to be kept 
in mind when using this technique (Ambrosino et al 2007b) 
(Table 2).
Acute hypercapnic respiratory failure 
following pneumonia
Clinical studies on the use of NPPV in acute hypoxemic 
respiratory failure due to community-acquired pneumonia International Journal of COPD 2008:3(4) 608
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(CAP) have yielded disappointing results (Ferrer et al 2003b; 
Honrubia et al 2005; Phua et al 2005). However, in patients 
with COPD and CAP at least one randomized controlled 
trial indicated beneﬁ  cial effects of NPPV on intubation 
rate, the duration of stay in the ICU and short-term survival 
(Confalonieri et al 1999).
Respiratory failure after extubation and during 
prolonged weaning
According to a large randomized controlled trials, in 
unselected patients NPPV seems not effective in reducing 
re-intubation rates, if used for the treatment of overt respira-
tory failure occurring after extubation (Esteban et al 2004; 
Keenan et al 2002). An even more critical issue seems to be 
that in the large study of Esteban and co-workers in which at 
least 10% of patients had COPD, even excess mortality was 
observed in the NPPV group during the ICU stay (Esteban 
et al 2004). However, the design of this trial has been criti-
cized on the basis of the argument that re-intubation in the 
NPPV group, occurring on average 10 hours later than in the 
control group, may have been delayed. In contrast to these 
ﬁ  ndings, a previous (although non-randomized) study in 
patients with COPD suggested a role for NPPV in the man-
agement of post-extubation hypercapnic respiratory failure 
based on the fact that it signiﬁ  cantly reduced the need for 
endotracheal intubation (Hilbert et al 1998).
Compared to this, a high level of evidence for the use of 
NPPV is available in patients with COPD and high risk for 
extubation failure, whereby NPPV is particularly utilized to 
avoid post-extubation respiratory failure and re-intubation. 
In this setting NPPV has been clearly shown in random-
ized controlled trials to reduce intubation rates and thereby 
improving ICU mortality, when NPPV is employed early 
after extubation, before the occurrence of overt respiratory 
failure (Ferrer et al 2006; Nava et al 2005).
Weaning from long-term invasive mechanical ventila-
tion often turns out to be a difﬁ  cult procedure in COPD; 
hence it is one of the major reasons for admission to 
specialized weaning-centers (Schonhofer et al 2002). 
NPPV has been proven to be useful in accelerating the 
weaning process when employed as a weaning strategy 
(Burns et al 2006). Speciﬁ  cally, randomized controlled 
design demonstrated that in patients who failed a T-piece 
trial, most of them having COPD, the rate of infectious 
complications, the duration of the ICU stay and short-term 
mortality were all reduced, when using additional NPPV 
versus standard weaning without NPPV (Ferrer et al 2003a; 
Nava et al 1998).
Invasive mechanical ventilation in COPD
Once the decision in favor of invasive ventilation has been 
made, care has to be taken that overstretching of lung paren-
chyma and ventilator-induced lung injury (VILI) are avoided 
(Tremblay et al 2006) by using low tidal volumes. One 
must state, however, that especially in patients with COPD 
Table 1 Most important predictors for treatment success/failure 
in acute hypercapnic respiratory failure in COPD derived from the 
literature (Ambrosino et al 1995; Brochard et al 1995; Carlucci 
et al 2001; Carlucci et al 2003; Confalonieri et al 2005; Conti et al 
2002; Meduri et al 1996; Phua et al 2005; Plant et al 2000a; Scala 
et al 2007; Soo Hoo et al 1994; Squadrone et al 2004), and Hill et al 
(2007) and Garpestad et al (2007)
Predictors for treatment 
success
Predictors for treatment 
failure
pH 7.25–7.35, PaCO2   45 mmHg pH   7.25
GCS   14 GCS   11
APACHE-II score   29 APACHE-II score   29;
Respiratory rate 24–30/min Signiﬁ  cant comorbidities
Response to NPPV within 1–2 h Respiratory rate   30/min
Training/experience of the team 
with NPPV
Additional pneumonia
Standardized NPPV protocol Severe mask leakage
Patient-ventilator asynchrony
Ineffective triggering
Agitation or intolerance
Encephalopathy
  Inability to clear secretions
Table 2 Relative and absolute contraindications for non-invasive 
ventilation in the acute and chronic setting, modiﬁ  ed from
Contraindications in acute
setting
Contraindications in chronic 
setting
Hemodynamic instability and 
cardiac arrest
Non-motivation or 
Non-adherence to therapy
Impending or manifest 
respiratory arrest
Mask intolerance (claustrophobia, 
facial dysmorphia)
Severely impaired consciousness Excessive secretions and/or risk 
for aspiration
Uncontrollable agitation Severe comorbidities or ethical 
concerns
Mask intolerance Severe cognitive impairment 
(dementia)
Signiﬁ  cant upper gastrointestinal 
bleeding
Lack of any subjective or objective 
treatment effect
Upper airway obstruction
Facial trauma or surgery
Massive secretions/aspiration risk  International Journal of COPD 2008:3(4) 609
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with severe exacerbation the impact of invasive ventilation 
on short- or long-term outcome has not yet been clearly 
shown, in contrast to patients with acute lung injury (ALI) 
or respiratory distress syndrome (ARDS) (ARDS Network 
2000). Small tidal volumes or low inspiratory pressure levels 
inevitably lead to a reduction of effective minute ventilation, 
with the consequence that PaCO2 raises and pH decreases. 
This may be tolerated down to pH values of 7.10–7.20. In 
fact a beneﬁ  cial effect of this “permissive hypercapnia” on 
short-term mortality has been found in different forms of 
acute lung injury and may also apply to COPD (Kregenow 
et al 2006).
Another adverse effect of invasive mechanical ventila-
tion in COPD is the generation or aggravation of PEEPi. 
This is typical for those diseases which are associated with 
signiﬁ  cant airway obstruction evoked by inﬂ  ammation, 
bronchospasm or hypersecretion, with the consequence 
of incomplete alveolar emptying and air trapping (Pfeifer 
2007). In controlled ventilation, a reduction of inspiratory 
time and respiratory frequency can increase expiratory time 
thus promoting lung deﬂ  ation with the consequence of a 
reduction in PEEPi (Ward et al 2008). The addition of an 
end-inspiratory pause is not favorable, as it impairs respira-
tory system mechanics and gas exchange (D’Angelo et al 
1994; Georgopoulos et al 1995; Wanger et al 1996). High 
initial ﬂ  ow rates can effectively reduce the work of breath-
ing particularly in patients with COPD undergoing pressure 
support ventilation (Bonmarchand et al 1996), while inad-
equate cycling may enhance dynamic hyperinﬂ  ation during 
assisted ventilation.
During patient-trigged support ventilation, PEEPi can 
represent a signiﬁ  cant load to the patient’s effort to trigger 
the ventilator. This can result in an increased work of breath-
ing und deleterious patient-ventilator asynchrony. In these 
circumstances the application of an external PEEP or its 
increase might be effective, as this reduces the trigger level 
and patient’s inspiratory threshold load. Patients with an 
excessive drive for breathing and concomitant high respira-
tory frequency will enhance their PEEPi. As a remedy, a 
higher level of sedation might be chosen, as far as tachypnea 
is not explained by other causes amenable to treatment, such 
as pain, fever and pulmonary embolism.
In the management of respiratory mechanics in COPD, 
the repeated analysis of wave forms including pressure-
volume loops can be particularly helpful in order to detect 
relevant changes in airway resistance and PEEPi, patient-
ventilator asynchrony, but also excessive airway secretions 
(Dhand 2005; Lucangelo et al 2005). An esophageal balloon 
allows even more sophisticated measurements, especially 
with regard to the work of breathing and chest wall or lung 
compliance (Dhand 2005).
Treatment of chronic respiratory 
failure
Mechanical ventilation in chronic 
hypercapnic respiratory failure
While the occurrence of acute hypercapnic respiratory failure 
in the course of an acute exacerbation in COPD is clearly 
associated with increased mortality, the prognostic value 
of chronic but stable hypercapnia is much more intricate 
(Budweiser et al 2007c). In patients with COPD and chronic 
respiratory failure receiving long-term oxygen therapy 
(LTOT), a low level of carbon dioxide tension (PaCO2) has 
even been found to be linked to elevated mortality (Chailleux 
et al 1996), whereas in another study similar rates of survival 
were observed in normocapnic ( 45 mmHg) and hypercap-
nic ( 45 mmHg) patients (Aida et al 1998). When PaCO2 
was markedly elevated ( 55 mmHg), long-term outcome 
within the ﬁ  rst year after hospital discharge was found to be 
poor (Chailleux et al 1996). The same applied when hyper-
capnia persisted after recovery from an acute exacerbation 
(Costello et al 1997).
Long-term non-invasive ventilation at home aims at 
persistently reducing hypercapnia as one of its goals. The 
impact of this treatment in COPD with chronic hypercapnic 
respiratory failure is still controversial, particularly as far as 
survival is taken as outcome measure. This is indicated by 
a number of randomized controlled trials (Budweiser et al 
2008b) which are however not devoid of methodological 
weaknesses (Elliott 2002; Kohnlein et al 2003). Despite 
these uncertainties, COPD with concomitant chronic hyper-
capnic respiratory failure has become one of the major 
indications for home mechanical ventilation (HMV), at least 
in Europe (Janssens et al 2003; Lloyd-Owen et al 2005). 
The large variability in prescription rates among different 
countries and institutions probably reﬂ  ects the fact that 
the criteria for initiating home ventilation in these patients 
differ, similarly to the conditions and traditions of health 
care systems. Throughout countries, home ventilation is 
predominantly administered through a nasal or facial mask 
during the night; only a minority of patients is ventilated 
invasively via tracheostoma (Farre et al 2005). Recent data 
indicate that invasive ventilation is associated with poorer 
long-term outcome particularly in patients with COPD 
(Marchese et al 2008).International Journal of COPD 2008:3(4) 610
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Indications for non-invasive home ventilation
and selection of patients
Following the currently accepted guidelines, a pronounced 
elevation of daytime PaCO2 is considered as a key indicator 
for the initiation of home mechanical ventilation in COPD 
(Rabe et al 2007). Noteworthy enough there seems to be 
no agreement on the required levels of hypercapnia, and 
these have never been veriﬁ  ed in comparative, prospective, 
randomized controlled trials. As a mark for orientation, the 
indication for non-invasive home ventilation in COPD is 
often based on the statements of a Consensus Conference 
Report a number of years ago (Consensus Conference Report 
1999). According to these, home mechanical ventilation can 
be justiﬁ  ed in severe COPD after optimization of standard 
therapy including LTOT, if daytime PaCO2 levels during 
spontaneous breathing are at least 55 mmHg. The same 
applies if PaCO2 levels are lower (50–54 mmHg) but at the 
same time signiﬁ  cant nocturnal hypoventilation is present 
(Table 3).
After initiation of HMV in patients with obstructive lung 
diseases beneﬁ  ts have been reported at least with regard to 
the frequency of hospitalizations compared to the preceding 
years (Jones et al 1998; Leger et al 1994). Thus, in more mild 
hypercapnia (PaCO2 50–54 mmHg) a further indication for 
home ventilation in COPD might be that at least two episodes 
of acute hypercapnic respiratory failure per year occur 
(Consensus Conference Report 1999). Such considerations 
suggest a role for HMV beyond the reversal of chronic 
hypercapnia as an immediate target.
According to the current view, COPD is considered as 
a systemic, multidimensional disorder bearing a variety of 
risk factors for severe exacerbations requiring hospitaliza-
tion (Garcia-Aymerich et al 2001; Kessler et al 1999) and 
for death from different causes (Dolan et al 2005). These 
risk factors favor disease instability, uncompensated respi-
ratory failure, and as a consequence hospitalization and 
death. A recent comprehensive meta-analysis came to the 
conclusion that in severe COPD HMV is capable of evoking 
beneﬁ  cial effects on the ventilatory pattern, thereby reduc-
ing the work of breathing and improving functional reserves 
(Kolodziej et al 2007). Correspondingly, the use of NPPV at 
home might be one important factor in counteracting episodes 
of impending respiratory failure, which in these multi-morbid 
patients easily result from exacerbations. Thus there seems 
to be enough reason for arguing that the eligibility for HMV 
should not be based on a too restrictive and simple pattern of 
criteria. Preferentially it should rely on a rational analysis of 
the individual patient’s risk factor proﬁ  le (Table 3). Such a 
view is also suggested by the results of a recent large obser-
vational study (Budweiser et al 2007b).
Moreover, a non-controlled investigation suggested that 
the continuation of HMV after difﬁ  cult or prolonged weaning 
was associated with better long-term survival, compared to 
patients discharged without ventilatory support. Interestingly 
enough, this was independent from the patients’ age and 
duration of hospital stay (Quinnell et al 2006). Thus careful 
administration of HMV in patients with COPD is not only 
likely to exert beneﬁ  cial effects on the patients but also might 
be beneﬁ  cial for the society, as it can result in a signiﬁ  cantly 
lower frequency of hospital admissions and a concomitant 
reduction in health-care costs, as noted previously (Casanova 
et al 2000; Jones et al 1998; Tuggey et al 2003). Whether this 
will lead to reduced or balanced overall costs, still has to be 
checked in prospective randomized controlled trials. Recent 
observational data suggest that long-term management of 
patients with severe COPD and chronic respiratory failure by 
measures including HMV does not increase healthcare costs 
compared to LTOT treatment alone (Clini et al 2008).
Effects of non-invasive home ventilation
Physiological mechanisms
It might seem surprising that the knowledge on the 
mechanisms underlying the effects of non-invasive HMV, 
especially their relative contributions under different condi-
tions, is still rather limited. In particular the basis for the 
Table 3 Indicators for the initiation of domiciliary non-invasive 
ventilation in COPD
Indications for domiciliary non-invasive ventilation
•  According to guidelines (Consensus Conference Report 1999)
Clinical symptoms (dyspnea, morning headache, daytime sleepiness) after 
optimization of standard therapy including oxygen
and
PaCO2   55 mmHg
or
PaCO2 50–54 mmHg
and
nocturnal SaO2   88% at night for  5 min with  2 L/min O2
or  2 hospitalizations per year because of acute respiratory failure
Further individually tailored indications (derived from observational 
studies):
•  After prolonged mechanical ventilation (Quinnell et al 2006)
•   After life-threatening exacerbation requiring ventilatory support 
(Chu et al 2004)
•   Patients at high risk for death, based on known risk factors (Budweiser 
et al 2007b)International Journal of COPD 2008:3(4) 611
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improvement of gas exchange during spontaneous breathing 
after NPPV support has not been clariﬁ  ed in detail (Mehta 
et al 2001). The hypothesis – plausible at the ﬁ  rst sight – that 
non-invasive ventilation primarily allows the exhausted 
respiratory muscles to rest and recover probably not properly 
accounts for the complex mechanisms involved (Budweiser 
et al 2008b). This is true despite the fact that ventilatory 
support can be associated with a reduction in the activa-
tion of respiratory muscles under certain circumstances, as 
shown in earlier studies (Carrey et al 1990; Nava et al 1993; 
Renston et al 1994).
However, restoration of chemosensitivity (Mehta et al 
2001) and changes in ventilatory pattern including an 
increase in tidal and minute volumes, as well as the con-
comitant reduction of respiratory frequency, may play a more 
prominent role in long-term NPPV. The relevance of these 
factors has been demonstrated in sophisticated physiological 
studies (Ambrosino et al 1992; Diaz et al 2002; Diaz et al 
2005b). Even more important seems to be that the ameliora-
tion of the ventilatory pattern is preserved during spontaneous 
breathing (Ambrosino et al 1992; Diaz et al 2002; Diaz et al 
2005b). This could well underlie the sustained reduction of 
PaCO2, which again induces positive effects on lung hyper-
inﬂ  ation and respiratory muscles (Budweiser et al 2005; 
Diaz et al 2002).
Subjective effects
The beneﬁ  cial effects of NPPV on breathing pattern, respira-
tory muscles and respiratory mechanics and the subsequent 
improvement in functional reserves (Kolodziej et al 2007) 
are reﬂ  ected in a reduction of dyspnea. Considering dyspnea 
as an integrative measure of efﬁ  cacy, this seems remarkable. 
It is a very consistent effect of long-term NPPV demonstrated 
by randomized controlled clinical trials (Casanova et al 2000; 
Clini et al 2002; Diaz et al 2005b). These ﬁ  ndings also ﬁ  t 
well into the picture provided by the data on health-related 
quality of life (HRQL).
The majority of controlled (Clini et al 2002; Meecham 
Jones et al 1995) and non-controlled trials (Perrin et al 1997; 
Sivasothy et al 1998; Windisch 2008) dealing with HRQL 
revealed positive effects of the long-term use of NPPV, irre-
spective of the fact whether generic measures were employed 
or disease-speciﬁ  c questionnaires designed for patients with 
chronic respiratory failure, such as the Maugeri Foundation 
Respiratory Failure Questionnaire (MRF-28) or the Severe 
Respiratory Insufﬁ  ciency (SRI) questionnaire. The latter has 
recently been validated especially with regard to COPD and 
HMV (Windisch et al 2008). This again seems an important 
result, since HRQL is an important marker in chronic 
hypercapnic respiratory failure and even might carry predic-
tive information on long-term survival, though this seems to 
depend on the type of disease (Budweiser et al 2007a).
Effects on exercise capacity
The patients’ global functional capacity appears to be well 
reﬂ  ected in the 6-minute walking distance (6-MWD) as a 
clinically useful and easy-to-assess measure (Carter et al 
2003). It also represents a prognostic marker in COPD 
(Pinto-Plata et al 2004), particularly in patients with chronic 
hypercapic respiratory failure (Budweiser et al 2008a). In 
the majority of studies there were no direct effects of long-
term NPPV on 6-MWD (Clini et al 2002; Meecham Jones 
et al 1995; Schonhofer et al 2007; Strumpf et al 1991), and 
6-MWD was found to be improved in only two randomized 
controlled trials which, however, covered only a short follow-
up time (Diaz et al 2005b; Renston et al 1994).
Obviously, while having positive effects at rest, intermit-
tent nocturnal HMV is not sufﬁ  cient to compensate for the 
worsening of dynamic hyperinﬂ  ation during exercise, which 
is considered as a major limiting factor of exercise capacity 
in severe COPD (O’Donnell et al 2001). This, however, does 
not exclude that NPPV applied during walking exerts posi-
tive effects on oxygenation, dyspnea and walking distance. 
Indeed such effects have been recently demonstrated in a 
randomized cross-over trial in a small sample of patients 
(Dreher et al 2007).
Effects on long-term survival
With regard to long-term prognosis the role of non-invasive 
ventilation in COPD and chronic hypercapnic failure is still 
under discussion. Two randomized controlled trials involv-
ing follow-up periods of 1 and 2 years, respectively, did not 
indicate domiciliary intermittent non-invasive ventilation 
to be effective in improving long-term survival compared 
to LTOT alone (Casanova et al 2000; Clini et al 2002). 
However, these trials comprised relatively small samples of 
patients and raised a number of objections regarding patients’ 
selection, ineffective ventilation or pressure levels, and poor 
adherence to therapy.
Thus non-randomized trials including a broad range of 
patients still seem to have a potential if analyzed and inter-
preted with caution. In a recent large observational study 
comprising an observation period of up to 4 years, we found 
that patients with COPD and non-invasive HMV showed 
a much better long-term survival than a control group of 
patients who could not be successfully adapted to HMV due International Journal of COPD 2008:3(4) 612
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to a variety of reasons (Budweiser et al 2007b). Of course, in 
view of the non-randomized design, these data have weak-
nesses, though the difference between treatment and control 
group at baseline was rather small. Still the results need to be 
checked by large randomized controlled trials, one such trial 
being currently underway (Kohnlein et al 2004).
Technical aspects of non-invasive home ventilation
One of the most important factors for a success of NPPV, 
especially a marked reduction in PaCO2, appears to be the 
achievement of effective ventilation by applying sufﬁ  cient 
levels of inspiratory pressure. In accordance with this, studies 
capable of demonstrating beneﬁ  cial effects of NPPV on gas 
exchange, lung function, sleep, or health-related quality of 
life (Budweiser et al 2005; Budweiser et al 2007c; Meecham 
Jones et al 1995; Windisch et al 2005) all used high inspi-
ratory pressures, up to 28 cm H2O, which were still well 
tolerated by the patients. In contrast, the application of lower 
inspiratory pressure levels (10–15 cm H2O), as chosen in the 
two available randomized controlled trials (Casanova et al 
2000; Clini et al 2002), was associated with an unfavorable 
outcome. Though these parallels are not compelling, they 
are at least suggestive.
During support-ventilation modes, in addition to 
high pressure levels, a positive end-expiratory pressure 
(3–5 cm H2O) and low trigger levels have been found to 
effectively counteract PEEPi (Nava et al 1993), minimizing 
the work of breathing and optimizing patient-ventilator 
synchrony. To allow for maximal expiratory emptying of the 
lung, inspiratory time should be chosen as short as possible 
when using controlled ventilation modes, with a target ratio 
of inspiration to expiration time (I:E) of at least 1:2 to 1:3.
Taking well-chosen ventilator settings and the usage of 
modern, sophisticated ventilators for granted, the potential of 
non-invasive ventilation can be fully utilized only if patients 
are motivated, well instructed and encouraged. This is of 
special importance in the initial phase of adaptation to the 
therapy. For achieving this, the availability of an experienced 
team as well as sufﬁ  cient time for familiarization within an 
in-patient setting appears of utmost value. Today the high 
rates of inacceptance as reported in the early years of HMV 
(Lin 1996; Strumpf et al 1991) would not be considered 
acceptable and justiﬁ  ed by objective reasons. Of course, con-
traindications have still to be taken into account (Table 2).
A further important issue is the regular follow-up of the 
patients. This serves for assessing the effectiveness of ventilation 
and adherence to therapy as well as for resolving potential adverse 
effects (Hill 2004). In case that an early withdrawal of NPPV 
turns out to be necessary, it should be noted that a beneﬁ  t from 
this therapy has been reported even for such short-term use (Diaz 
et al 2002; Diaz et al 2005b). Obviously NPPV can be efﬁ  cient 
even if bolstering functional reserves only within a short episode 
of most severe, acute deterioration (Budweiser et al 2008b).
Oxygen therapy
Physiological consequences of hypoxemia
Once acute hypoxemia reaches a critical limit, various 
physiological consequences take place. These include an 
increase in minute ventilation, compensatory tachycardia 
to increase cardiac output, dilation of peripheral vessels, 
and constriction of pulmonary vasculature, with the result 
of a reduction of ventilation/perfusion mismatching. In the 
long run, these events plus the stimulation of erythropoietin 
production causing polycythemia lead to functional and 
structural changes including cor pulmonale and pulmonary 
hypertension (Kim et al 2008). Beyond its effects on the 
cardiopulmonary system, hypoxemia causes a number of 
other consequences, which include the reduction of speciﬁ  c 
neurocognitive functions as well as non-speciﬁ  c symptoms 
such as headache, thoracic oppression and agitations.
Oxygen for acute hypoxemic 
respiratory failure
Based on the physiological responses to hypoxemia, the 
administration of oxygen during acute respiratory failure as 
indicated by acute hypoxia and dyspnea can be considered 
as a matter of course. Accordingly, in current guidelines 
(Rabe et al 2007) for the management of acute exacerbations 
in COPD it is recommended that “the ﬁ  rst actions when a 
patient reaches the emergency department are to provide 
supplemental oxygen therapy and to determine whether the 
exacerbation is life threatening”. Although this intervention 
is well established in clinical practice and oxygen supply is 
considered as biologically justiﬁ  ed, the evidence on oxygen 
supply in acute respiratory failure from randomized con-
trolled trials is surprisingly limited (Schumaker et al 2004).
It must however be admitted that appropriate clinical 
trials are difﬁ  cult to perform in such clinically unstable 
conditions (Plant et al 2003) and moreover encounter ethical 
concerns. Short-term clinical trials in patients with COPD and 
stable hypoxemia and current pathophysiological concepts 
of dyspnea (O’Donnell et al 2007) suggest that oxygen is 
effective both in improving oxygen saturation and in reduc-
ing breathlessness in the acute setting. The alleviation of 
symptoms is presumably related to the decreases in minute 
ventilation and/or respiratory rate, which reduce the work International Journal of COPD 2008:3(4) 613
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of breathing and the risk for respiratory decompensation 
(Aubier et al 1980a).
To achieve these effects and sufﬁ  cient levels of oxygenation, 
(PaO2   60 mmHg or oxygen saturation (SaO2)  90%) 
(Rabe et al 2007), nasal prongs or high ﬂ  ow devices (Venturi 
masks) may be used, the latter being more reliable for deliv-
ering a deﬁ  ned oxygen amount in the acute setting (Bazuaye 
et al 1992). It is currently unknown whether the delivery 
of oxygen in the presence of PaO2 values  60 mmHg is 
beneﬁ  cial in acute exacerbations. In any case, short-term and 
repeated evaluations of gas exchange indices are commonly 
recommended to verify treatment effects and to exclude 
a signiﬁ  cant CO2 retention or an impending respiratory 
acidosis that may result from the reduction in hypoxic drive 
to breathe, or ventilation/perfusion mismatching (Aubier et al 
1980b; Robinson et al 2000). As yet, clinical investigations 
dealing with these safety issues in, however, small samples of 
patients have suggested that the risk of worsening an existing 
hypercapnia is low during controlled oxygen delivery in acute 
exacerbations (Agusti et al 1999; Gomersall et al 2002). It 
may predominantly occur in patients with very severe initial 
hypercapnia (Moloney et al 2001).
The idea has been proposed that inhalation of nitric 
oxide in addition to oxygen might have beneﬁ  ts compared to 
oxygen alone in patients with COPD. There is, however, no 
substantial evidence on clinically relevant add-on effects, as 
indicated by studies that found unchanged, or even impaired, 
oxygenation in patients of different severity (Kanniess et al 
2001; Melsom et al 2007). As a consequence, this combined 
therapy is not recommended in COPD (Germann et al 2005). 
More promising seems the addition of a helium-oxygen 
mixture based on the ﬂ  uid-mechanical and physiological 
properties of helium. This has the potential to provide ben-
eﬁ  ts regarding a reduction of airway resistance and work 
of breathing, which might result in lower intubation rates 
compared to standard inhalation gas (Schumaker et al 2004). 
However, these ﬁ  ndings have to be substantiated in future 
randomized controlled trials.
Long-term oxygen therapy for chronic 
hypoxemic respiratory failure
LTOT is widely accepted as treatment to counterbalance 
chronic, signiﬁ  cant hypoxemia in COPD although it is 
known to represent a considerable amount of still increas-
ing health-care costs (Croxton et al 2006). Despite this, it 
has been argued that the critical PaO2 levels allowing the 
prescribing of LTOT according to accepted guidelines (Rabe 
et al 2007) (Table 4) are probably not fully adequate. They do 
not properly take into account other important factors of 
the disease such as a low BMI, comorbidities, or frequent 
exacerbations, all of which may favor a beneﬁ  t from LTOT 
(O’Reilly et al 2007).
Effects of LTOT on survival
Among the treatment modalities for COPD, LTOT is consid-
ered since many years as one of those interventions for which a 
clear-cut survival beneﬁ  t is given. Indeed, more than 25 years 
ago two randomized controlled trials were capable of demon-
strating a survival beneﬁ  t from LTOT in patients with severe 
COPD and persistent hypoxemia at rest (MRC 1981; NOTT 
1980). The patients included in these long-term trials either 
showed an arterial PaO2 level  55 mmHg or of  59 mmHg 
in case of additional peripheral edema, polycythemia or signs 
for cor pulmonale (NOTT 1980), or they showed PaO2 levels 
ranging from 40 to 60 mmHg and coexisting hypercapnia or 
congestive heart failure (MRC 1981). These two clinical trials 
represent major advances in respiratory medicine and are most 
often used as scientiﬁ  c basis for the prescription of LTOT.
Despite this one should not ignore their limitations, 
among them the relatively small numbers of patients (n = 87 
and n = 203, respectively) compared to present-day standards 
and changes in overall treatment regimes in the meantime 
(Kim et al 2008). Nevertheless, there was an impressive ben-
eﬁ  t regarding long-term survival in patients receiving LTOT, 
which was closely related to the amount of daily use. The 
effect on long-term prognosis was particularly pronounced 
in patients using oxygen on average  15 or  16 hours/day, 
respectively. Viewed from the other side, such treatments 
effects have highlighted the major role of chronic hypoxemia 
as a predictor of long-term survival in COPD (Dolan et al 
2005), and long-term follow-up investigations have essen-
tially conﬁ  rmed this relationship (Aida et al 1998; Chailleux 
et al 1996; Dubois et al 1994).
In contrast to the more severely affected patients, 
those with more mild daytime resting hypoxemia, ie, PaO2 
Table 4 Major indications for long-term oxygen therapy (LTOT) 
summarized from GOLD guidelines (Rabe et al 2007) and national 
standards (BTS 1997; Magnussen et al 2001; NICE 2004)
Indications for Long-term oxygen therapy
PaO2   55 mmHg or SaO2   88% at rest during daytime spontaneous 
breathing
PaO2   55 but  60 mmHg in the presence of polycythemia, evidence or 
signs for cor pulmonale or pulmonary hypertension
During special conditions in patients without daytime hypoxemia but 
PaO2   55 mmHg during sleep or exercise (when CPAP is not indicated)International Journal of COPD 2008:3(4) 614
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levels   55 mmHg (Gorecka et al 1997) or  60 mmHg 
(Fletcher et al 1992), did not show signiﬁ  cant responses to 
LTOT in terms of survival within randomized controlled 
trials. The same was found for patients without marked 
daytime hypoxemia but nocturnal desaturations (Chaouat 
et al 1999; Fletcher et al 1992). A potential limitation of these 
studies, however, is that the daily average time of oxygen 
use may have been too short to induce recognizable survival 
beneﬁ  ts in less ill patients.
Effects of oxygen on other outcomes
Supplemental oxygen has been shown to reduce the sensation 
of dyspnea and to improve exercise capacity in patients with 
resting daytime hypoxemia (Lane et al 1987; Swinburn et al 
1991). Such beneﬁ  cial short-term effects during exercise can 
also been achieved in milder forms of hypoxemia, which 
do not reach the critical limit for the deﬁ  nition of hypoxic 
respiratory failure (PaO2   60 mmHg) at rest (Dean et al 
1992; Fujimoto et al 2002). Presumably the underlying 
mechanisms involve a decrease in minute ventilation and 
concomitantly dynamic hyperinﬂ  ation. These are accom-
panied by improvements in pulmonary hemodynamics and 
oxygen delivery which improve respiratory muscle function 
(Kim et al 2008).
Additionally there is evidence that in patients with 
chronic hypoxemia LTOT can induce subjective beneﬁ  ts 
regarding the presence of neurophysiological symptoms, 
anxiety, depression and health-related quality of life (HRQL) 
(Eaton et al 2004; Heaton et al 1983). In patients showing 
only transient hypoxemia during exercise, the randomized 
controlled trials have provided only mixed evidence regard-
ing effects of LTOT on HRQL (Eaton et al 2002; McDonald 
et al 1995; Nonoyama et al 2007). Similarly, the rationale for 
administering supplemental oxygen during sleep in patients 
showing only nocturnal desaturations has not yet been clearly 
supported by data. Accordingly, a recent comprehensive pro-
spective study indicated that nocturnal desaturations are not 
linked to impairments of HRQL, sleep quality and daytime 
vigilance (Lewis et al 2008).
In addition to the favorable results of LTOT on survival, 
beneﬁ  cial effects on pulmonary hemodynamics have been 
described (NOTT 1980), which was essentially conﬁ  rmed 
by later investigations (Zielinski et al 1998). This association 
probably represents an indirect, not a direct, causal relation-
ship. Irrespective of this it may signiﬁ  cantly contribute to 
the positive effects of LTOT on mortality and hospitaliza-
tion rate (Ringbaek et al 2002), as pulmonary hypertension 
and cor pulmonale are known to be major factors in the 
long-term outcome of patients with COPD (Kessler et al 
1999; Oswald-Mammosser et al 1995). Taken together, these 
results indicate that in patients without daytime hypoxemia 
but PaO2   55 mmHg during sleep or exercise, LTOT has to 
be considered. This particularly applies in the case that the 
optimization of other treatments such as CPAP that might 
also be sometimes indicated does not sufﬁ  ce to reverse 
hypoxemia (Table 4).
In summary, the following statements can be made on 
the basis of the data described.
•  In severe acute exacerbations of COPD with acute respi-
ratory failure, controlled oxygen delivery is a reasonable 
and effective approach to relieve symptoms, counteract 
hypoxemia and reduce the work of breathing.
•  In COPD with acute hypercapnic respiratory failure, non-
invasive ventilation is highly recommended, particularly 
in patients with mild to moderate respiratory acidosis. 
Non-invasive ventilation has the potential to reduce the 
risk for invasive ventilation and the associated complica-
tions, as well as to improve overall ICU and in-hospital 
outcome.
•  In COPD with clinically relevant chronic hypoxemia, 
LTOT is strongly indicated to improve hemodynamic 
parameters, long-term prognosis and HRQL.
•  In COPD with chronic hypercapnic respiratory failure, 
the role of long-term non-invasive home ventilation 
for survival has not yet been unambiguously demon-
strated. However, a number of investigations point 
towards signiﬁ  cant beneﬁ  ts in subjective and physiologi-
cal outcomes.
•  Taken together, respiratory failure in COPD must be 
considered as a serious or even life-threatening com-
plication. Controlled oxygen supply and non-invasive 
mechanical ventilation are two effective components 
of an evidence-based, comprehensive management of 
respiratory failure. Their rational use has the potential 
to signiﬁ  cantly ameliorate the patients’ symptoms and 
to improve survival.
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